Rakovina Therapeutics Inc. (RKVTF)

Rakovina Therapeutics Income Statement

Financials in millions CAD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	2.42	1.45	0.81	0.87	0.97	0
Research & Development	2.79	2.34	1.67	1.95	1.5	-
Operating Expenses	5.21	3.79	2.48	2.82	2.47	0
Operating Income	-5.21	-3.79	-2.48	-2.82	-2.47	-0
Interest Expense	-0.27	-0.27	-0.15	-	-	-
Interest & Investment Income	0	0.01	0.02	0.03	0.01	-
Currency Exchange Gain (Loss)	-0	-0	-0	-0	-0	-
Other Non Operating Income (Expenses)	-	-	-	-	-3.05	-
EBT Excluding Unusual Items	-5.48	-4.05	-2.61	-2.79	-5.52	-0
Other Unusual Items	-0.02	-0.02	-	-	-	-
Pretax Income	-5.5	-4.07	-2.61	-2.79	-5.52	-0
Net Income	-5.5	-4.07	-2.61	-2.79	-5.52	-0
Net Income to Common	-5.5	-4.07	-2.61	-2.79	-5.52	-0
Shares Outstanding (Basic)	100	83	70	70	54	-
Shares Outstanding (Diluted)	100	83	70	70	54	-
Shares Change (YoY)	43.35%	18.18%	0.03%	30.22%	-	-
EPS (Basic)	-0.05	-0.05	-0.04	-0.04	-0.10	-
EPS (Diluted)	-0.06	-0.05	-0.04	-0.04	-0.10	-
EBITDA	-4.67	-3.25	-1.95	-2.28	-2.06	-
D&A For EBITDA	0.54	0.54	0.54	0.54	0.41	-
EBIT	-5.21	-3.79	-2.48	-2.82	-2.47	-0

Source: S&P Global Market Intelligence. Standard template. Financial Sources.